A claims-data study of more than 2,000 children and adolescents has quantified a pediatric risk of GLP-1 therapy that prescribing patterns have largely ignored: nearly one in six young patients was diagnosed with a nutritional deficiency within a year of starting treatment.
What Happened
Researchers at Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University analyzed national insurance claims covering more than 100 million patients, identifying 2,031 GLP-1 users aged 10 to 17 with no prior deficiency diagnosis. Within 12 months of starting treatment, 16.8 percent had a diagnosed nutritional deficiency or nutrition-related health problem.
Vitamin D deficiency led, affecting 12.4 percent of the children, followed by nutritional anemia at roughly 1.6 percent and iron-deficiency anemia at 1.4 percent. The study was published in the journal Childhood Obesity on September 23, 2026.
Most prescriptions in the cohort were for liraglutide (78.6 percent), with dulaglutide at 10.4 percent and semaglutide at 9.1 percent, reflecting the study's 2017-2022 claims window.
Timeline
- 2017-2022 — Claims window analyzed by the research team
- September 23, 2026 — Study published in Childhood Obesity
- Follow-up period — Deficiency diagnoses tracked across the first 12 months of GLP-1 therapy
Who Is Affected
- Children and adolescents prescribed GLP-1s for obesity, prediabetes, or type 2 diabetes, during peak growth years
- Prescribers — The study found only 5 percent of patients received nutritional counseling within 30 days of starting, and fewer than 25 percent within six months
- Parents managing appetite suppression in growing children
- Compounded-GLP-1 buyers — unregulated sources add dosing uncertainty on top of nutritional risk
What This Means for Researchers
- Appetite suppression has a developmental cost. Vitamin D, iron, and calcium deficiencies during adolescence can carry lasting implications for skeletal health and development, the senior author noted
- The counseling gap is the actionable finding. Deficiencies were largely diagnosed after the fact; the authors argue nutritional management should start at prescription, not at diagnosis
- The cohort skews older-generation. Liraglutide dominated the sample; today's pediatric semaglutide era may show a different risk profile
- Context is growing use. GLP-1 prescriptions in young children have jumped hundreds-fold, mostly off-label, making prospective pediatric safety data urgent
How to Verify Your Peptides
- If a child's GLP-1 came from an unregulated source, identity and purity testing matters even more during development — see our semaglutide testing guide
- Start with how third-party peptide testing works
Safe Alternatives
- Read our semaglutide research profile for the published pediatric and adult trial data
- See our earlier coverage of GLP-1 prescriptions in young children
- Compare sources in our vetted vendor directory
Sources
Peer-reviewed research published in Childhood Obesity, September 2026; hospital and university announcements; industry reports.